诱导多能干细胞：帕金森病建模的工具。
Induced pluripotent stem cells: a tool for modeling Parkinson's disease.
机构信息
Ann Romney Institute of Neurological Diseases, Harvard Medical School/Brigham and Women's Hospital, Boston, MA, USA.
Ann Romney Institute of Neurological Diseases, Harvard Medical School/Brigham and Women's Hospital, Boston, MA, USA.
出版信息
Trends Neurosci. 2022 Aug;45(8):608-620. doi: 10.1016/j.tins.2022.05.001. Epub 2022 Jun 3.
Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder. Among its pathologies, progressive loss of dopaminergic (DA) neurons in the substantia nigra is characteristic and contributes to many of the most severe symptoms of PD. Recent advances in induced pluripotent stem cell (iPSC) technology have made it possible to generate patient-derived DA neuronal cell culture and organoid models of PD. These models have contributed to understanding disease mechanisms and the identification of novel targets and therapeutic candidates. Still needed are better ways to model the age-related aspects of PD, as well as a deeper understanding of the interactions among disease-modifying genes and between genetic and environmental contributions to the etiology and progression of PD.
摘要
帕金森病（PD）是第二大常见的神经退行性疾病。在其病理学中，黑质中多巴胺能（DA）神经元的进行性丧失是其特征，并导致 PD 的许多最严重症状。诱导多能干细胞（iPSC）技术的最新进展使得生成患者来源的 DA 神经元细胞培养物和 PD 类器官模型成为可能。这些模型有助于理解疾病机制以及确定新的靶点和治疗候选物。仍然需要更好的方法来模拟 PD 的与年龄相关的方面，以及更深入地了解疾病修饰基因之间的相互作用以及遗传和环境因素对 PD 的病因和进展的贡献。
相似文献
1
Induced pluripotent stem cells: a tool for modeling Parkinson's disease.诱导多能干细胞：帕金森病建模的工具。
Trends Neurosci. 2022 Aug;45(8):608-620. doi: 10.1016/j.tins.2022.05.001. Epub 2022 Jun 3.
2
Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells.利用患者特异性诱导多能干细胞建立帕金森病模型。
J Parkinsons Dis. 2018;8(4):479-493. doi: 10.3233/JPD-181353.
3
Modeling Parkinson's disease with induced pluripotent stem cells harboring α-synuclein mutations.利用携带α-突触核蛋白突变的诱导多能干细胞建立帕金森病模型。
Brain Pathol. 2017 Jul;27(4):545-551. doi: 10.1111/bpa.12526.
4
Parkinson's disease in a dish - Using stem cells as a molecular tool.在培养皿中研究帕金森病——以干细胞为分子工具。
Neuropharmacology. 2014 Jan;76 Pt A:88-96. doi: 10.1016/j.neuropharm.2013.08.035. Epub 2013 Sep 10.
5
Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.使用患者来源的诱导多能干细胞来鉴定帕金森病相关表型。
Curr Neurol Neurosci Rep. 2018 Oct 4;18(12):84. doi: 10.1007/s11910-018-0893-8.
6
Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.帕金森病患者（PARK4）中 SNCA 三重复制诱导多能干细胞源性多巴胺能神经元中的α-突触核蛋白动力学。
FEBS Open Bio. 2021 Feb;11(2):354-366. doi: 10.1002/2211-5463.13060. Epub 2021 Jan 5.
7
Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery.类器官和多能干细胞在帕金森病模型中的应用：专家对其在药物发现中的价值的看法。
Expert Opin Drug Discov. 2020 Apr;15(4):427-441. doi: 10.1080/17460441.2020.1703671. Epub 2020 Jan 3.
8
Modeling Parkinson's disease using induced pluripotent stem cells.利用诱导多能干细胞来模拟帕金森病。
Curr Neurol Neurosci Rep. 2012 Jun;12(3):237-42. doi: 10.1007/s11910-012-0270-y.
9
From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson's Disease Modeling and Regenerative Therapy.从 2D 到 3D：用于帕金森病建模和再生治疗的单层多巴胺能神经元和中脑组织类器官培养的发展。
Int J Mol Sci. 2023 Jan 28;24(3):2523. doi: 10.3390/ijms24032523.
10
Dissecting the non-neuronal cell contribution to Parkinson's disease pathogenesis using induced pluripotent stem cells.利用诱导多能干细胞解析帕金森病发病机制中的非神经元细胞贡献。
Cell Mol Life Sci. 2021 Mar;78(5):2081-2094. doi: 10.1007/s00018-020-03700-x. Epub 2020 Nov 18.
引用本文的文献
1
Morphological profiling reveals neuroprotection via mitochondrial uncoupling in human dopaminergic neurons.形态学分析揭示了人类多巴胺能神经元中线粒体解偶联介导的神经保护作用。
Sci Rep. 2025 Aug 12;15(1):29507. doi: 10.1038/s41598-025-14735-0.
2
Stem Cells and Organoids: A Paradigm Shift in Preclinical Models Toward Personalized Medicine.干细胞与类器官：临床前模型向个性化医学转变的范例。
Pharmaceuticals (Basel). 2025 Jul 1;18(7):992. doi: 10.3390/ph18070992.
3
Understanding the Pre-Clinical Stages of Parkinson's Disease: Where Are We in Clinical and Research Settings?了解帕金森病的临床前期阶段：我们在临床和研究方面进展如何？
Int J Mol Sci. 2025 Jul 17;26(14):6881. doi: 10.3390/ijms26146881.
4
Advances, challenges, and opportunities of human midbrain organoids for modelling of the dopaminergic system.用于多巴胺能系统建模的人类中脑类器官的进展、挑战与机遇
EMBO J. 2025 Jul 2. doi: 10.1038/s44318-025-00494-1.
5
Induced Pluripotent Stem Cells Derived Cellular Models for Investigating Parkinson's Disease Pathogenesis and Drug Screening.用于研究帕金森病发病机制和药物筛选的诱导多能干细胞衍生细胞模型
Stem Cell Rev Rep. 2025 Oct;21(7):1883-1900. doi: 10.1007/s12015-025-10931-7. Epub 2025 Jun 30.
6
Clearance Pathways for α-Synuclein in Parkinson's Disease.帕金森病中α-突触核蛋白的清除途径
J Neurochem. 2025 Jun;169(6):e70124. doi: 10.1111/jnc.70124.
7
Current Development of iPSC-Based Modeling in Neurodegenerative Diseases.基于诱导多能干细胞的神经退行性疾病建模的当前进展
Int J Mol Sci. 2025 Apr 16;26(8):3774. doi: 10.3390/ijms26083774.
8
Chemical-based epigenetic reprogramming to advance pluripotency and totipotency.基于化学方法的表观遗传重编程以提升多能性和全能性。
Nat Chem Biol. 2025 May;21(5):635-647. doi: 10.1038/s41589-025-01874-8. Epub 2025 Apr 18.
9
Cell reprogramming: methods, mechanisms and applications.细胞重编程：方法、机制与应用
Cell Regen. 2025 Mar 27;14(1):12. doi: 10.1186/s13619-025-00229-x.
10
Regenerating Locus Coeruleus-Norepinephrine (LC-NE) Function: A Novel Approach for Neurodegenerative Diseases.恢复蓝斑-去甲肾上腺素（LC-NE）功能：一种治疗神经退行性疾病的新方法。
Cell Prolif. 2025 Jun;58(6):e13807. doi: 10.1111/cpr.13807. Epub 2025 Jan 28.
本文引用的文献
1
Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia.LRRK2 基因突变与帕金森病相关，将 Rab8a 隔离到受损的溶酶体中，并调节小胶质细胞中转铁蛋白介导的铁摄取。
PLoS Biol. 2021 Dec 16;19(12):e3001480. doi: 10.1371/journal.pbio.3001480. eCollection 2021 Dec.
2
Rescue of α-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking.协同增强内质网蛋白稳态和蛋白质转运以挽救帕金森病患者神经元中的α-突触核蛋白聚集。
Neuron. 2022 Feb 2;110(3):436-451.e11. doi: 10.1016/j.neuron.2021.10.032. Epub 2021 Nov 17.
3
The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.帕金森病相关突变 LRRK2-G2019S 通过 NR2F1 改变多巴胺能分化动力学。
Cell Rep. 2021 Oct 19;37(3):109864. doi: 10.1016/j.celrep.2021.109864.
4
Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models.抗精神病药喹硫平直接靶向野生型葡萄糖脑苷脂酶，改善帕金森病模型中的致病表型。
JCI Insight. 2021 Oct 8;6(19):e148649. doi: 10.1172/jci.insight.148649.
5
Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology.家族性帕金森病患者诱导多能干细胞衍生的多巴胺能神经元显示α-突触核蛋白病理学和异常的线粒体形态。
Cells. 2021 Sep 13;10(9):2402. doi: 10.3390/cells10092402.
6
The AKT modulator A-443654 reduces α-synuclein expression and normalizes ER stress and autophagy.AKT 调节剂 A-443654 可降低α-突触核蛋白表达并使内质网应激和自噬正常化。
J Biol Chem. 2021 Oct;297(4):101191. doi: 10.1016/j.jbc.2021.101191. Epub 2021 Sep 11.
7
In Parkinson's patient-derived dopamine neurons, the triplication of α-synuclein locus induces distinctive firing pattern by impeding D2 receptor autoinhibition.在帕金森病患者来源的多巴胺神经元中，α-突触核蛋白基因三重复导致 D2 受体自身抑制受阻，从而诱导出独特的放电模式。
Acta Neuropathol Commun. 2021 Jun 7;9(1):107. doi: 10.1186/s40478-021-01203-9.
8
Astrocytic atrophy as a pathological feature of Parkinson's disease with LRRK2 mutation.星形胶质细胞萎缩作为携带LRRK2突变的帕金森病的一种病理特征。
NPJ Parkinsons Dis. 2021 Mar 30;7(1):31. doi: 10.1038/s41531-021-00175-w.
9
Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes.LRRK2 激酶活性的增加通过破坏自噬体的轴突运输来改变神经元的自噬。
Curr Biol. 2021 May 24;31(10):2140-2154.e6. doi: 10.1016/j.cub.2021.02.061. Epub 2021 Mar 24.
10
Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.帕金森病患者携带 LRRK2 G2019S 突变的 iPSCs 源性多巴胺能神经元中多巴胺 D3 和烟碱型乙酰胆碱受体膜定位受损。
Neurobiol Aging. 2021 Mar;99:65-78. doi: 10.1016/j.neurobiolaging.2020.12.001. Epub 2020 Dec 8.
Zotero 插件